NURIX THERAPEUTICS INC (NRIX)
Health Care · NASDAQ
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi.
What NURIX THERAPEUTICS INC does
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and inflammatory diseases. The company leverages its proprietary DEL-AI platform, combining AI-integrated discovery with advanced chemistry synthesis and direct-to-biology technologies, to develop protein degraders and degrader antibody conjugates (DACs). Its pipeline includes clinical-stage programs targeting BTK (Bruton's tyrosine kinase) for B-cell malignancies and CBL-B inhibitors for immuno-oncology, with collaboration agreements for co-development with Gilead, Sanofi, and Pfizer.
Themes: ["protein degradation / PROTACs"]
Fundamentals
- Price$24.69 as of 2026-07-09 close
- Market cap$2.6B as of 2026-07-10
- 1-year return+99.1% as of 2026-07-09 close
- Net margin-411.4% as of 2026-07-10
- ROE-64.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+27.2% as of 2026-07-10
- Revenue CAGR (3y)+29.5% SEC XBRL
- Beta1.77 as of 2026-07-10
Key risks (from latest filing)
["Clinical stage company with no approved products; pipeline dependent on successful Phase 1b/2 trials for bexobrutideg and zelebrudomide; regulatory approvals uncertain."]
Competitors & peers
- Genentech/Roche (now partnered with Nurix on bexobrutideg)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.